Oligodendrocyte extracellular vesicles: a novel therapy for CNS autoimmunity
少突胶质细胞外囊泡:中枢神经系统自身免疫的新疗法
基本信息
- 批准号:10115612
- 负责人:
- 金额:$ 39万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-03-01 至 2025-02-28
- 项目状态:未结题
- 来源:
- 关键词:AddressAnimal ModelAnimalsAntigen TargetingAntigensAutoantigensAutoimmuneAutoimmune DiseasesAutoimmune ResponsesAutoimmunityCNS autoimmunityCell LineCellsChronicClinicalDataDevelopmentDiseaseEpitope spreadingEpitopesEvolutionExperimental Animal ModelExperimental Autoimmune EncephalomyelitisFailureFlareGeneticGoalsHeterogeneityHumanImmune TargetingImmune ToleranceImmune responseImmune systemImmunityImmunizationImmunosuppressionInjectionsInterferon Type IIInterferonsInterleukin-10IntravenousKnockout MiceKnowledgeMediatingModelingMultiple SclerosisMusMyelinMyelin ProteinsNoseOligodendrogliaOralPathogenesisPathogenicityPatientsPeptidesPeripheralProductionResearchRestRoleRouteSerious Adverse EventSpecificitySystemTestingTherapeuticTherapeutic AgentsTherapeutic EffectTimeTranslationsTreatment EfficacyUncertaintybaseclinically relevantconditional knockoutextracellular vesicleshumanized mouseimmune system functionimmunoregulationin vivomultiple sclerosis patientneuroinflammationnovel therapeuticsparticleperipheral toleranceprogrammed cell death ligand 1prophylacticreconstitutionresponseside effectsuccessvesicular release
项目摘要
SUMMARY: Oligodendrocyte extracellular vesicles: a novel therapy for CNS autoimmunity.
Current therapies for multiple sclerosis (MS) target the immune system in an antigen (Ag)-nonspecific manner,
with potentialy serious side effects due to systemic immunosuppression. A longstanding goal in MS research is
to devise an Ag-specific therapy that would suppress only harmful immune responses, while leaving the rest of
the immune system intact. The prerequisite for Ag-specific therapy is identification of the target Ag. MS
pathogenesis is widely believed to be driven by autoimmunity against myelin Ags. However, the relevant Ag(s)
in MS remains speculative, with the possibility that these Ags differ among patients, and over time in the same
patient. Numerous approaches for Ag-specific suppression of autoimmune neuroinflammation have been proven
in experimental autoimmune encephalomyelitis (EAE), an animal model of MS. These approaches rely on re-
establishing peripheral tolerance for self-Ag by delivering the same self-Ag in a non-inflammatory context (eg. in
PBS) via various routes, such as intravenous (i.v.), oral, or nasal. However, translation of these experimental
strategies into MS therapy has been hampered by uncertainty about the relevant Ags in MS patients. In
addressing this issue, we reasoned that if for tolerance induction we used oligodendrocyte (Ol)-derived
extracellular vesicles (Ol-EVs), which naturally contain most or all of the myelin Ags, it would be unnecessary to
identify the relevant myelin Ag(s) in each patient. Further, we also posited that i.v. injection of Ol-EVs will
suppress EAE, similar to well-documented i.v. tolerance induction by free self-peptide. Indeed, our data show
that Ol-EVs contained all the relevant myelin Ags and upon i.v. injection ameliorated ongoing EAE in an Ag-
dependent manner, suggesting that Ol-EVs can be a universal therapeutic agent for MS. Based on these and
additional preliminary data, we hypothesize that human and mouse Ol-EVs contain all relevant myelin Ags, and
upon i.v. administration will ameliorate EAE induced by various myelin Ags. We additionally hypothesize that this
effect is Ag-dependent and mediated by the IFN-/IL-27/PD-L1 axis. This hypothesis will be tested in the following
specific aims: Aim 1. To determine the therapeutic efficacy of Ol-EVs in several EAE models. Since the
significance of this project is to study Ol-EVs as a potential therapy for MS, and we do not know the relevant
Ag(s) in MS, we will test the hypothesis that OL-EVs/i.v. can suppress EAE induced by any myelin Ag, because
all the relevant Ags are present in OL-EVs. Aim 2. To define the mechanism of EAE suppression by Ol-EVs.
Our preliminary data provide a basis for the hypothesis that Ol-EVs/i.v. induce tolerogenic APCs, which diminish
pathogenic Th cell response and suppress EAE via expression of immunoregulatory molecules. Aim 3. To study
the effects of human Ol-EVs in human myelin Ag-induced EAE, and in humanized mice. We will optimize
production of human Ol-EVs, and test the hypothesis that human Ol-EVs/i.v. have adequate therapeutic efficacy
in EAE models, and in humanized mice to determine if findings in mice are paralleled in this human-like system.
摘要:少突胶质细胞胞外囊泡:治疗中枢神经系统自身免疫的新方法。
目前多发性硬化症(MS)的治疗以抗原(Ag)非特异性方式针对免疫系统,
由于全身免疫抑制,可能会有严重的副作用。多发性硬化研究的一个长期目标是
设计一种针对抗原的治疗方法,只抑制有害的免疫反应,而让其余的
免疫系统完好无损。抗原特异性治疗的前提是确定靶标抗原。女士
发病机制被广泛认为是由抗髓鞘AGS的自身免疫所驱动的。不过,相关的银(S)
多发性硬化症仍是一种推测,有可能这些AGS在不同的患者之间,随着时间的推移是相同的
有耐心的。许多针对抗原特异性抑制自身免疫性神经炎的方法已被证明
在实验性自身免疫性脑脊髓炎(EAE)中,MS的动物模型。
通过在非炎症性环境中提供相同的自体银来建立外周对自体银的耐受性(例如,在……里面
PBS)通过各种途径,例如静脉注射、口服或鼻腔注射。然而,这些实验性的翻译
MS患者中相关AGS的不确定性阻碍了MS治疗策略的实施。在……里面
针对这一问题,我们推断,如果我们使用少突胶质细胞(Ol)来源的耐受诱导
细胞外小泡(Ol-EVS),它自然包含大部分或全部髓鞘AGs,不需要
确定每个患者的相关髓鞘银(S)。此外,我们还假设了静脉注射。注入Ol-EVS将
抑制EAE,类似于有充分证据的静脉注射。游离自体多肽诱导耐受性。事实上,我们的数据显示
Ol-Evs包含了所有相关的髓鞘AGS和On静脉注射。注射改善正在进行的银屑病患者的EAE
依赖的方式,表明Ol-EVS可以作为MS的通用治疗剂。
更多的初步数据,我们假设人和小鼠的OL-EV含有所有相关的髓鞘抗原,并且
静脉注射。给药可改善各种髓鞘AGS所致的EAE。我们还假设这一点
作用依赖于抗原,并由干扰素-/IL-27/PD-L1轴介导。这一假设将在以下方面得到检验
目的:1.确定OL-EVS对几种EAE模型的治疗效果。自.以来
本项目的意义在于研究OL-EVS作为一种潜在的治疗MS的方法,我们还不知道相关的
AG(S)在MS中,我们将检验OL-EVS/i.V.的假设。能抑制任何髓磷脂抗原诱导的EAE,因为
所有相关的AGS都存在于OL-EVS中。目的2.明确OL-EVS抑制EAE的机制。
我们的初步数据为Ol-EVS/i.v.诱导产生耐受性的APC,它会减少
致病Th细胞通过免疫调节分子的表达应答和抑制EAE。目标3.学习
人Ol-Evs对人髓鞘抗原诱导的EAE和人源化小鼠的影响。我们将优化
生产人OL-EVS,并检验人OL-EVS/IV.有足够的治疗效果
在EAE模型和人源化小鼠中,以确定小鼠的发现是否与这个类似人类的系统相似。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
A.M. Rostami其他文献
A.M. Rostami的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('A.M. Rostami', 18)}}的其他基金
IL-37: a novel regulator of inflammation in CNS autoimmunity
IL-37:中枢神经系统自身免疫炎症的新型调节剂
- 批准号:
10199564 - 财政年份:2021
- 资助金额:
$ 39万 - 项目类别:
IL-37: a novel regulator of inflammation in CNS autoimmunity
IL-37:中枢神经系统自身免疫炎症的新型调节剂
- 批准号:
10369694 - 财政年份:2021
- 资助金额:
$ 39万 - 项目类别:
Oligodendrocyte extracellular vesicles: a novel therapy for CNS autoimmunity
少突胶质细胞外囊泡:中枢神经系统自身免疫的新疗法
- 批准号:
10361415 - 财政年份:2020
- 资助金额:
$ 39万 - 项目类别:
Mechanisms of GM-CSF effect in CNS autoimmune demyelination
GM-CSF在中枢神经系统自身免疫性脱髓鞘中的作用机制
- 批准号:
10062792 - 财政年份:2016
- 资助金额:
$ 39万 - 项目类别:
The Role of GM-CSF in the Pathogenesis of Multiple Sclerosis
GM-CSF 在多发性硬化症发病机制中的作用
- 批准号:
8767198 - 财政年份:2014
- 资助金额:
$ 39万 - 项目类别:
The Role of GM-CSF in the Pathogenesis of Multiple Sclerosis
GM-CSF 在多发性硬化症发病机制中的作用
- 批准号:
8911388 - 财政年份:2014
- 资助金额:
$ 39万 - 项目类别:
相似海外基金
Quantification of Neurovasculature Changes in a Post-Hemorrhagic Stroke Animal-Model
出血性中风后动物模型中神经血管变化的量化
- 批准号:
495434 - 财政年份:2023
- 资助金额:
$ 39万 - 项目类别:
Small animal model for evaluating the impacts of cleft lip repairing scar on craniofacial growth and development
评价唇裂修复疤痕对颅面生长发育影响的小动物模型
- 批准号:
10642519 - 财政年份:2023
- 资助金额:
$ 39万 - 项目类别:
Bioactive Injectable Cell Scaffold for Meniscus Injury Repair in a Large Animal Model
用于大型动物模型半月板损伤修复的生物活性可注射细胞支架
- 批准号:
10586596 - 财政年份:2023
- 资助金额:
$ 39万 - 项目类别:
A Comparison of Treatment Strategies for Recovery of Swallow and Swallow-Respiratory Coupling Following a Prolonged Liquid Diet in a Young Animal Model
幼年动物模型中长期流质饮食后吞咽恢复和吞咽呼吸耦合治疗策略的比较
- 批准号:
10590479 - 财政年份:2023
- 资助金额:
$ 39万 - 项目类别:
Diurnal grass rats as a novel animal model of seasonal affective disorder
昼夜草鼠作为季节性情感障碍的新型动物模型
- 批准号:
23K06011 - 财政年份:2023
- 资助金额:
$ 39万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Longitudinal Ocular Changes in Naturally Occurring Glaucoma Animal Model
自然发生的青光眼动物模型的纵向眼部变化
- 批准号:
10682117 - 财政年份:2023
- 资助金额:
$ 39万 - 项目类别:
A whole animal model for investigation of ingested nanoplastic mixtures and effects on genomic integrity and health
用于研究摄入的纳米塑料混合物及其对基因组完整性和健康影响的整体动物模型
- 批准号:
10708517 - 财政年份:2023
- 资助金额:
$ 39万 - 项目类别:
A Novel Large Animal Model for Studying the Developmental Potential and Function of LGR5 Stem Cells in Vivo and in Vitro
用于研究 LGR5 干细胞体内外发育潜力和功能的新型大型动物模型
- 批准号:
10575566 - 财政年份:2023
- 资助金额:
$ 39万 - 项目类别:
Elucidating the pathogenesis of a novel animal model mimicking chronic entrapment neuropathy
阐明模拟慢性卡压性神经病的新型动物模型的发病机制
- 批准号:
23K15696 - 财政年份:2023
- 资助金额:
$ 39万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
The effect of anti-oxidant on swallowing function in an animal model of dysphagia
抗氧化剂对吞咽困难动物模型吞咽功能的影响
- 批准号:
23K15867 - 财政年份:2023
- 资助金额:
$ 39万 - 项目类别:
Grant-in-Aid for Early-Career Scientists